A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)

Starting soon · Phase 1

Conditions studied: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis

In brief

Researchers are studying MK-8527, a new medicine for preventing HIV-1 (human immunodeficiency virus type 1) infection and want to learn if MK-8527 can be given together with rifampin. Rifampin is commonly used to treat people with latent tuberculosis infection (LTBI). The main goal of this study is to learn what happens to MK-8527 in the body over time when given with and without the medication rifampin in participants with LTBI.

Key facts

Study ID: NCT07600775
Run by: Merck Sharp & Dohme LLC
People needed: 14
Starts: 2026-09-01
Expected to finish: 2027-01-19
Last updated by the study team: 2026-08-03

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

The main inclusion criteria include but are not limited to the following:
Has a diagnosis of untreated latent tuberculosis infection (LTBI)
Has no symptoms of active tuberculosis (TB)
Has never received treatment for TB or LTBI
Other than having LTBI, is in good health

You may not qualify if…

The main exclusion criteria include but are not limited to the following:
Has a diagnosis of LTBI made in the context of an outbreak/contact-tracing investigation
Has a current or anticipated immunocompromised state
Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
Has a history of cancer (malignancy)
Has a history of active TB
Has positive test results for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.